M&A - ABVC BIOPHARMA, INC.

Form Type: 8-K/A

Filing Date: 2025-07-18

Corporate Action: Acquisition

Type: Update

Accession Number: 000121390025065728

Filing Summary: On July 15, 2025, ABVC BioPharma, Inc. entered into a Definitive Agreement for the acquisition of land from Shuling Jiang, a director of the Company. This transaction involves the transfer of land located in Taoyuan City, Taiwan, in exchange for 2,035,136 shares of common stock valued at approximately $3,857,975 and warrants to purchase an additional 1,000,000 shares at $2.50 per share. The agreement addresses related party concerns due to Jiang's ownership of over 8% of common stock. Jiang will also receive compensation for consulting services with a payment of $1 million, structured as 1 million shares over five years. If the Company delists from the Nasdaq or undergoes a change of control, Jiang retains the right to reclaim the land. The deal was approved by shareholders at the Annual Meeting on June 3, 2025. Following the deal, Jiang's ownership could potentially rise to 23.3% depending on further share issuances.